Restricted accessOtherFirst published online 2010-05
Long-term anxiolytic and antidepressant-like behavioural effects of tiagabine,a selective GABA transporter-1 (GAT-1) inhibitor,coincide with a decrease in HPA system activity in C57BL/6 mice
Gamma-aminobutyric acid (GABA) system plays a pivotal role in the pathophysiology of anxiety and mood disorders. This study was aimed to assess the anxiolytic and antidepressant-like properties of tiagabine, an inhibitor of the GABA transporter-1 (GAT-1), after acute and chronic administration in C57BL/6JOlaHsD mice with paroxetine as a positive control. In first experiments, the acute administration of tiagabine (7.5 mg/kg, orally [PO]) and paroxetine (10 mg/kg PO) induced anxiolytic effects in the elevated plus maze test and the modified hole board test and an antidepressant-like effect in the forced swim test. Chronic application of tiagabine (7.5 mg/kg PO) and paroxetine (10 mg/kg PO) for 22 days revealed an anxiolytic and antidepressant-like efficacy of tiagabine only. In a further experiment, we analysed the impact of chronic tiagabine versus paroxetine treatment on the hypothalamic-pituitary-adrenocortical (HPA) system regulation. GAT-1 blockade induced a setpoint-shift of the stress hormone system toward lower levels as indicated by decreased plasma corticosterone concentrations and attenuated gene expression levels of corticotropin-releasing factor in the paraventricular nucleus of the hypothalamus and of hippocampal steroid receptors. This data indicate that both acute and long-term anxiolytic and antidepressant-like properties of brain GAT-1 inhibition coincide with a reduction in HPA system activity in mice.
Aldenkamp, AP, De Krom, M., Reijs, R. ( 2003) Newer antiepileptic drugs and cognitive issues . Epilepsia44: 21-29.
2.
Beaufour, CC, Balon, N., Le Bihan, C., Hamon, M., Tiebot, MH ( 1999) Effects of chronic antidepressants in an operant conflict procedure in the rat. Pharmacol Biochem Behav62: 141-149.
3.
Belzung, C. ( 2001) The genetic basis of the pharmacological effects of anxiolysis: a review based on rodent models. Behav Pharmacol12: 451-460.
4.
Borden, LA, Murali Dhar, TG, Smith, KE, Weinshank, RL, Branchek, TA, Gluchowski, C. ( 1994) Tiagabine, SK and F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol269: 219-224.
5.
Borsini, F., Podhorna, J., Marazziti, D. ( 2002) Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology163: 121-141.
6.
Boyle, MP, Brewer, JA, Funatsu, M., Wozniak, DF, Tsien, JZ, Isumi, Y., et al. (2005) Acquired deficit of forebrain glucocorticoid receptor produces depression-like changes in adrenal axis regulation and behavior . Proc Natl Acad Sci102: 473-478.
Burghardt, NS, Sullivan, GM, McEwen, BS, Gorman, JM, LeDoux, JE ( 2004) The selective reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: A comparison with tianeptine. Biol Psychiatry55: 1171-1178.
9.
Cai, YQ, Cai, GQ, Liu, GX, Cai, Q., Shi, JH, Shi, J., et al. (2006) Mice with genetically altered GABA transporter I (GAT1) expressionj show altered behavioral responses to ethanol. J Neurosci Res84: 255-267.
10.
Carpenter, LL, Schecter, JM, Tyrka, AR, Mello, AF, Mello, MF, Haggarty, R., et al. (2006) Open-label Tiagabine Monotherapy for Major Depressive Disorder with Anxiety. J Clin Psychiatry67: 66-71.
11.
Chiu, C., Brickley, S., Jensen, K., Southwell, A., McKinney, S., Cull-Candy, S., et al. (2005) GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum . J Neurosci25: 3234-3245.
12.
Connor, KM, Davidson, JRT, Weisler, RH, Zhang, W., Abraham, K. ( 2006) Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology184: 21-25.
13.
Crawley, JN ( 2000) What’s wrong with my mouse? Behavioral phenotyping of transgenic and knockout mice. John Wiley & Sons , Chichester.
14.
Cryan, JF, Markou, A., Lucki, I. ( 2002) Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci23: 238-245.
15.
Cryan, JF, Kaupmann, K. ( 2005) Don’t worry "B" happy!: a role for GABAB receptors in anxiety and depression. Trends Pharmacol Sci26: 36-43.
16.
Cryan, JF, Holmes, A. ( 2005) The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov4: 775- 790.
17.
Dalby, NO ( 2003) Inhibition of gamma-aminobutyric acid uptake: anatomy, physiology and effects against epileptic seizures. Eur J Pharmac479: 127-137.
18.
David, DJP, Renard, CE, Jolliet, P., Hascoet, M., Bourin, M. ( 2003) Antidepressant-like effects in various mice strains in the forced swimming test. Psychopharmacology166: 373-382.
19.
de Kloet, ER, Joels, M., Holsboer, F. ( 2005) Stress and the brain: from adaptation to disease . Nat Rev Neurosci6: 463-475.
20.
Dulawa, SC, Holick, KA, Gundersen, B., Hen, R. ( 2004) Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology29: 1321-1330.
Erhardt, A., Ising, M., Unschuld, PG, Kern, N., Lucae, S., Pütz, B., et al. (2006) Regulation of the hypothalamic-pituitary-adrenocortical system in patients with panic disorder. Neuropsychopharmacology31: 2515-2522.
23.
Gao, B., Cutler, MG ( 1994) Effects of acute and chronic administration of the antidepressants, imipramine, phenelzine and mianserine, on the social behavior of mice. Neuropharmacology33: 813-824.
24.
Goddard, AW, Mason, GF, Almai, A., Rothman, DL, Behar, KL, Petroff, OAC, et al. (2001) Reductions in occipital cortex GABA levels in panic disorder detected with 1H-magnetic resonance spectroscopy. Arch Gen Psychiatry58: 556-561.
25.
Griebel, G. ( 1995) 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research. Pharmac Ther65: 319-395.
26.
Hasler, G., van der Veen, JW, Tumonis, T., Meyers, N., Shen, J., Drevets, WC ( 2007) Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry64: 193-200.
27.
Herman, JP, Figueiredo, H., Mueller, NK, Ulrich-Lai, Y., Ostrander, MM, Choi, DC, et al. (2003) Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness . Front Neuroendocrinol24: 151-180.
28.
Heuser, IJ, Yassouridis, A., Holsboer, F. ( 1994) The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders. J Psychiatr Res28: 341-356.
29.
Holsboer, F. ( 2000) The corticosteroid receptor hypothesis of depression . Neuropsychopharmacology23: 477-501.
30.
Holsboer, F. ( 2003) High-Quality Antidepressant Discovery by Understanding Stress Hormone Physiology. Ann N Y Acad Sci1007: 394-404.
31.
Ising, M., Horstmann, S., Kloiber, S., Lucae, S., Binder, EB, Kern, N., et al. (2007) Comined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker? Biol Psychiatry62: 47-54.
32.
Jensen, K., Chiu, CS, Sokolova, I., Lester, HA, Mody, I. ( 2003) GABA transporter-1 (GAT1)-deficient mice: Differential tonic activation of GABAA versus GABAB receptors in the hippocampus. J Neurophysiol90: 2690-2701.
33.
Kalueff, AV, Nutt, DJ ( 2007) Role of GABA in anxiety and depression. Depress Anxiety24: 495-517.
34.
Keck, ME, Welt, T., Müller, MB, Uhr, M., Ohl, F., Wigger, A., et al. (2003) Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology28: 235-243.
35.
Kurt, M., Arik, AC, Celik, S. ( 2000) The effects of sertraline and fluoxetine on anxiety in the elevated plus-maze test in mice. J Basic Clin Physiol Pharmacol11: 173-180.
36.
Lader, M. ( 1994) Anxiolytic drugs: dependence, addiction and abuse . Eur Neuropsychopharmacol4: 85-91.
37.
LaRoche, SM, Helmers, SL ( 2004) The new antiepileptic drugs: scientific review . JAMA291: 605-614.
38.
Liu, GX, Cai, GQ, Cai, YQ, Sheng, ZJ, Jiang, J., Mei, Z., et al. (2007) Reduced anxiety and depression-like behaviors in mice lacking GABA transporter subtypeI. Neuropsychopharmacology32: 1531-1539.
39.
Lucki, I., Dalvi, A., Mayorga, AJ ( 2001) Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology155: 315-322.
40.
Millan, MJ ( 2003) The neurobiology and control of anxious states . Prog Neurobiol70: 83-244.
41.
Minelli, A., Brecha, NC, Karschin, C., DeBiasi, S., Conti, F. ( 1995) GAT-1, a high-affinity GABA plasma membrane transporter, is located to neurons and astroglia in the cerebral cortex. J Neurosci15: 7734-7746.
42.
Möhler, H. ( 2007) Molecular regulation of cognitive functions and developmental plasticity: impact of GABAA receptors. J Neurochem102: 1-12.
43.
Mombereau, C., Kaupmann, K., Froestl, W., Gilles, S., van der Putten, H., Cryan, JF ( 2004) Genetic and pharmacological evidence of a role for GABAB receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology29: 1050-1062.
44.
Montkowski, A., Barden, N., Wotjak, C., Stec, I., Ganster, J., Meaney, M., et al. (1995) Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. J Neuroendocrinol7: 841-845.
45.
Nakagawa, Y., Ishima, T., Takashima, T. ( 1999) The GABA(B) receptor antagonist CGP36742 improves learned helplessness in rats. Eur J Pharmacol381: 1-7.
Nguyen, SA, Deleon, CP, Malcolm, RJ, Middaugh, LD ( 2005) Tiagabine reduces ethanol reward in C57BL/6 mice under acute and chronic administration regimens. Synapse56: 135-146.
48.
Nickel, T., Sonntag, A., Schill, J., Zobel, AW, Ackl, N., Brunnauer, A., et al. (2003) Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J Clin Psychopharmacol23: 155-168.
49.
Nielsen, EB, Suzdak, PD, Andersen, KE, Knutsen, LJS, Sonnewald, U., Braestrup, C. ( 1991) Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol196: 257-266.
50.
Norcross, M., Poonam, M., Enoch, AJ, Karlsson, RM, Brigman, JL, Cameron, HA, et al. (2008) Effects of adolescent fluoxetine treatment on fear-, anxiety- or stress-related behaviors in C57BL/6J or BALB/cJ mice . Psychopharm200: 413-424.
51.
Nusser, Z., Mody, I. ( 2002) Selective modulation of tonic and phasic inhibitions in dentate gyrus granule cells. J Neurophysiol87: 2624-2628.
52.
Nutt, DJ, Malizia, AL ( 2001) New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiat179: 390-396.
53.
Ohl, F., Holsboer, F., Landgraf, R. ( 2001a) The modified hole board as differential screen for behavior in rodents. Behav Res Methods Instrum Comput33: 392-397.
54.
Ohl, F., Sillaber, I., Binder, E., Keck, ME, Holsboer, F. ( 2001b) Differential analysis of basal behavior and diazepam-induced alterations in C57BL/6 and BALB/c mice using the modified hole board. J Psychiatr Res35: 147-154.
55.
Overstreet, LS, Westbrook, GL ( 2003) Synapse density regulates independence at unitary inhibitory synapses. J Neurosci23: 2618-2626.
56.
Pollack, MK, Roy-Byrne, PP, Van Ameringen, M., Snyder, H., Brown, C., Ondrasik, J., et al. (2005) The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry66: 1401-1408.
57.
Pollack, MH, Jensen, JE, Simon, NM, Kaufman, RE, Renshaw (2008) High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to levetiracetam. Prog Neuropsychopharmacol Biol Psychiartry32: 739-743.
58.
Porsolt, RD, La Pichon, M., Jalfre, M. ( 1977) Depression: a new animal model sensitive to antidepressant treatments. Nature266: 730-732.
59.
Reijs, R., Aldenkamp, AP, de Krom, M. ( 2004) Mood effects of antiepileptic drugs. Epilepsy Behav5 (Suppl 1): S66-S76.
60.
Reul, JM, Stec, I., Söder, M., Holsboer, F. ( 1993) Chronic treatment of rats with the antidepressant amitritptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system . Endocrinology133: 312-320.
61.
Rodgers, RJ, Dalvi, A. ( 1997) Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev21: 801-810.
62.
Rodgers, RJ, Cutler, MG, Jackson, JE ( 1997) Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline and fluvoxamine. II. The elevated plus-maze. Pharmacol Biochem Behav57: 127-136.
63.
Rogawski, MA, Loescher, W. ( 2004) The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med10: 685-692.
64.
Rosenthal, M. ( 2003) Tiagabine for the treatment of generalized anxiety disorders: a randomized, open-label, clinical trial with paroxetine as a positive control . J Clin Psychiatry64: 1245-1249.
65.
Sanacora, G., Mason, GF, Rothman, DL, Krystal, JH ( 2002) Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors . Am J Psychiatry159: 663-665.
66.
Sanacora, G., Gueorguieva, R., Epperson, N., Wu, YT, Appel, M., Rothman, DL, et al. (2004) Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry61: 705-713.
67.
Schmidt, M., Oitzl, MS, Müller, MB, Ohl, F., Wurst, W., Holsboer, F., et al. (2003) Regulation of the developing hypothalamic-pituitary-adrenal axis in CRH receptor 1 deficient mice. Neuroscience119: 589-595.
68.
Schmidt, MV, Sterlemann, V., Ganea, K., Liebl, C., Alam, S., Harbich, D., et al. (2007) Persistent neuroendocrine and behavioral effects of a novel, etiologically relevant mouse paradigm for chronic social stress during adolescence. Psychoneuroendocrino32: 417-429.
69.
Schmitt, U., Hiemke, C. ( 1999) Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze. Behav Pharmacol19: 131-137.
70.
Schmitt, U., Lüddens, H., Hiemke, C. ( 2001) Behavioral analysis indicates benzodiazepine-tolerance mediated by the benzodiazepine binding-site at the GABAA-receptor. Prog Neuropsychopharmacol Biol Psychiatry25: 1145-1160.
71.
Schmitt, U., Lüddens, H., Hiemke, C. ( 2002) Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats. J Neural Transm109: 871-880.
72.
Suzdak, PD ( 1994) Lack of tolerance to the anticonvulsant effects of tiagabine following chronic (21 day) treatment. Epilepsy Res19: 205-213.
73.
Swan, M., Najlerahim, A., Watson, RE, Bennett, JP ( 1994) Distribution of mRNA for the GABA transporter GAT-1 in the rat brain: evidence that GABA uptake is not limited to presynaptic neurons . J Anat185: 315-323.
74.
Taylor, FB ( 2003) Tiagabine for posttraumatic stress disorder: a case series of 7 women. J Clin Psychiatry64: 1421-1425.
75.
Thoeringer, CK, Sillaber, I., Roedel, A., Erhardt, A., Mueller, MB, Ohl, F., et al. (2007) The temporal dynamics of intrahippocampal corticosterone in response to stress-related stimuli with different emotional and physical load: An in vivo microdialysis study in C57BL/6 and DBA/2 inbred mice. Psychoneuroendocrino32: 746- 757.
76.
Thoeringer, CK, Ripke, S., Unschuld, PG, Lucae, S., Ising, M., Bettecken, T., et al. (2008) The GABA transporter 1: A novel candidate for anxiety disorders. J Neural Transm, DOI 10.1007/s00702-008-0075-y.
77.
Thomsen, C., Suzdak, PD ( 1995) Effects of chronic tiagabine treatment on [3H]GABAA, [3H]GABAB and [3H]tiagabine binding to sections from mice brain. Epilepsy Res21: 79-88.
78.
Tran, V., Hatalski, CG, Yan, XX, Baram, TZ ( 1999) Effects of blocking GABA degradation on corticotropin-releasing hormone gene expression in selected brain regions. Epilepsia40: 1190-1197.
79.
Van Rijnsoever, C., Täuber, M., Choulli, MK, Keist, R., Rudolph, U., Möhler, H., et al. (2004) Requirement of α5-GABAA receptors for the development of tolerance to the sedative action of diazepam in mice. J Neurosci24: 6785-6790.
80.
Welt, T., Engelmann, M., Renner, U., Erhardt, A., Müller, MB, Landgraf, R., et al. (2006) Temazepam triggers the release of vasopressin into the rat hypothalamic paraventricular nucleus: Novel insight into benzodiazepine action on hypothalamic-pituitary-adrenocortical system activity during stress . Neuropsychopharmacology31: 2573-2579.
81.
Zwanzger, P., Baghai, T., Schüle, C., Minov, C., Padberg, F., Möller, HJ, et al. (2001a) Tiagabine improves panic and agoraphobia in panic disorder patients. J Clin Psychiatry62: 656-657.
82.
Zwanzger, P., Baghai, T., Schüle, C., Ströhle, A., Padberg, F., Kathmann, N., et al. (2001b) Viagabatrin decreases cholezystokinin tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology25: 699-703.
83.
Zwanzger, P., Eser, D., Aicher, S., Schüle, C., Baghai, T., Padberg, F., et al. (2003a) Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis acitivity: A placebo-controlled study. Neuropsychopharmacology28: 979-984.
84.
Zwanzger, P., Eser, D., Padberg, F., Baghai, T., Schüle, C., Rötzer, F., et al. (2003b) Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4) induced anxiety in healthy volunteers. Depression and Anxiety18: 140-143.
85.
Zwanzger, P., Rupprecht, R. ( 2005) Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci30: 167-175.
